ForPatients
by Roche

Alzheimer's Disease (AD) Neurodegenerative Disorder

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Trial Status	Trial Runs In	Trial Identifier
Terminated	15 Countries	NCT03444870 2017-001364-38 WN29922

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 116. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.

Hoffmann-La Roche	Phase 3
Sponsor	Phase

NCT03444870 2017-001364-38 WN29922
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 50 Years & <= 90 Years	No